Are you curious about nicotine pouches, a new type of flavoured nicotine product? Learn about their market, popularity, side effects, health implications, and safety in this informative article.
Discover the growing trend of celebrities using nicotine pouches, a smokeless and discreet alternative to tobacco products. Find out which famous people are using nicotine pouches and why they prefer them.
Photo by abvrockgroup on Pixabay
Swedish snus, a smokeless tobacco product, is known for its unique flavor and appeal. Many individuals are curious about the nicotine content in snus and how it affects the body. In this article, we will delve into the science behind nicotine absorption in Swedish snus. By understanding the process of nicotine uptake and its effects on the body, individuals can make informed decisions about their tobacco use.
When using snus, only a portion of the nicotine present in the product is released and absorbed by the body. Research has shown that less than half of the nicotine present in a pinch of snus is extracted during use (Adlkofer et al., 1995). This means that the actual amount of nicotine absorbed is significantly lower than the total nicotine content in the snus.
Nicotine in snus is absorbed through the buccal mucosa, which is the lining of the mouth. Studies have revealed that only 10-20% of the nicotine present in a pinch of snus is absorbed through the buccal mucosa and reaches the systemic circulation (Andersson et al., 1994). This means that for a one gram pinch of snus containing approximately 10 mg of nicotine, only 1-2 mg of nicotine is actually absorbed into the blood.
Nicotine is absorbed quite rapidly from Swedish snus. Research has shown that the nicotine concentration in the blood increases by approximately 10 ng/ml within the first 10 minutes of snus use (Holm et al., 1992). After this initial spike, the absorption rate slows down, and the plasma concentration of nicotine reaches a plateau. This differs from smoking, where nicotine is rapidly absorbed through the lungs and eliminated quickly after finishing a cigarette.
Snus users and cigarette smokers who have similar blood nicotine levels also report similar levels of subjective dependence on tobacco (Lee, 2011). Studies have shown that the plasma steady-state levels of nicotine and its main metabolite, cotinine, are comparable in both snus users and cigarette smokers (Holm et al., 1992). This suggests that the effects of nicotine on the body, as well as the addictive potential, are similar regardless of the method of tobacco consumption.
In a study comparing snus users and cigarette smokers, participants were asked to assess their addiction, craving for tobacco, and difficulty in giving up (Holm et al., 1992). The results showed no significant difference between snus users and cigarette smokers in these measures. This indicates that snus users experience similar subjective effects and dependence on tobacco as cigarette smokers.
To estimate the daily nicotine uptake from snus, researchers have measured the total amount of nicotine and its metabolites excreted in urine over a 24-hour period (Andersson et al., 1997). This method provides a more accurate measurement of nicotine intake compared to using cotinine as a biomarker.
Studies have shown that the total daily nicotine uptake is similar in habitual snus users and cigarette smokers, amounting to approximately 25 mg (Andersson et al., 1997). This indicates that snus users consume a similar amount of nicotine as cigarette smokers.
Unlike cigarette smokers, snus users do not compensate for lower nicotine content by increasing their consumption. When snus users switch to a low nicotine product, their nicotine uptake decreases by approximately 50% (Andersson et al., 1997). This suggests that snus users do not feel the need to compensate for lower nicotine levels and adjust their consumption accordingly.
The nicotine dose from various portion-packed snus products can vary. A controlled cross-over study compared the nicotine intake from different snus products with a 2 mg nicotine chewing gum (Lunell et al., 2005). The results showed that the nicotine dose from a 0.3 g portion-packed snus was approximately 0.4 mg, while a 0.5 g portion-packed snus contained approximately 0.8 mg of nicotine. The two 1 gram portion-packed snus products had nicotine doses of 0.9 and 1.2 mg, respectively.
Understanding the science behind nicotine absorption in Swedish snus provides valuable insights into the effects of snus on the body. While nicotine is absorbed quite rapidly from snus, only a portion of the nicotine present in the product is actually absorbed through the buccal mucosa. Snus users and cigarette smokers have similar levels of nicotine and cotinine in their blood, indicating comparable physiological effects and addictive potential. The total daily nicotine uptake in snus users is similar to that of cigarette smokers. Additionally, snus users do not compensate for lower nicotine levels by increasing their consumption. By gaining a deeper understanding of nicotine absorption in snus, individuals can make informed choices regarding their tobacco use.
Adlkofer, F.X. 1995. Involvement of nicotine and its metabolites in the pathology of smoking-related diseases: Facts and hypothesis. In: P.B.S. Clarke, M. Quik, F. Adlkofer. & K. Thurau (Eds.), Advances in Pharmacological Sciences, Effects of Nicotine on Biological Systems II. (pp. 17-25). Basel, Boston, Berlin: Birkhauser Verlag.
Andersson, G., Bjornberg, G., and Curvall, M. 1994. Oral mucosal changes and nicotine disposition in users of Swedish smokeless tobacco products: A comparative study. J. Oral Pathol. Med. 23:161-167.
Andersson, G., Axell, T., and Curvall, M. 1995. Reduction in nicotine intake and oral mucosal changes among users of Swedish oral moist snuff after switching to a low-nicotine product. J. Oral Pathol. Med. 24:244-250.
Andersson, G., Vala E.K., and Curvall, M. 1997. The influence of cigarette consumption and smoking machine yields of tar and nicotine on the nicotine uptake and oral mucosal lesions in smokers. J. Oral Pathol. Med. 26:117-123.
Benowitz, N.L., Jacob, P. III, and Yu, L. 1989. Daily use of smokeless tobacco: systemic effects. Ann. Int. Med. 111:112-116.
Holm, H., Jarvis, M.J., Russell, M.A.H., Feyerabend, C. 1992. Nicotine intake and dependence in Swedish snuff takers. Psychopharmacology 108:507-511.
Larsson, I., Curvall, M., and Enzell, C.R. 1987. Disposition of nicotine and cotinine in plasma, saliva and urine of snuff-users. Proceedings from Third European Congress of Biopharmaceutics and Pharmacokinetics: pp. 318-24.
Lee, P.N. Summary of the epidemiological evidence relating snus to health. Regulatory Toxicology and Pharmacology 59 (2011) 197-214.
Lunell, E. and Lunell, M. 2005. Steady-state nicotine plasma levels following use of four different types of Swedish snus compared with 2-mg Nicorette chewing gum: A crossover study. Nicotine & Tobacco Research 7:1-7.
Wennmalm, Å., Benthin, G., Granstrom, E.F., Persson, L., Petersson, L., and Winell, S. 1991. Relation between tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in young men. Circulation 83:1698-1704.
© All rights reserved!
